TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.24
-0.01 (-2.04%)
At close: 3:28PM EST
Stock chart is not supported by your current browser
Previous Close0.25
Open0.25
Bid0.23 x 0
Ask0.25 x 0
Day's Range0.24 - 0.25
52 Week Range0.19 - 0.55
Volume47,250
Avg. Volume274,601
Market Cap30.356M
Beta0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.40
  • FSCWire14 days ago

    Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers, announced today that the sixth patient in a nine patient Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) was enrolled and treated on February 7, 2018, using the Company’s anti-cancer technology. The Study is being used to evaluate the Company’s lead PDC drug for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue).

  • FSCWirelast month

    Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    January 18, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 10, 2018, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.

  • FSCWirelast month

    Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 11, 2017, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.

  • Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
    FSCWirelast month

    Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer has announced an optimization to the delivery schedule of its proprietary anti-cancer vaccine, increasing its efficacy in the destruction of brain cancer. The anti-cancer vaccine was evaluated in a rat glioma (“RG2”) animal model, an established model of Glioblastoma Multiforme (“GBM”), a deadly form of human brain cancer.

  • ACCESSWIRElast month

    Today’s Research Reports on Emblem Corp., Cronos Group Inc., Calyx Bio-Ventures Inc. and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE3 months ago

    Theralase Discovers Theralase(R) Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments

    TORONTO, ON / ACCESSWIRE / November 30, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQX: TLTFF ) ( FSE: TTX ), a leading biotech company ...

  • ACCESSWIRE3 months ago

    Theralase Increases Revenue 12% for 3Q2017 Financial Statements

    TORONTO, ON / ACCESSWIRE / November 29, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • ACCESSWIRE3 months ago

    Theralase Therapeutic Laser Technology Enhances Cancer Destruction

    TORONTO, ON / ACCESSWIRE / November 27, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • ACCESSWIRE3 months ago

    Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer

    TORONTO, ON / ACCESSWIRE / November 22, 2017 / Theralase Technologies Inc. ('' Theralase® '' or the '' Company '') ( TSX-V: TLT ) ( OTCQX: TLTFF ) ( FSE: TTX ), a leading biotech company focused on the ...

  • ACCESSWIRE3 months ago

    Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug

    TORONTO, ON / ACCESSWIRE / November 21, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on the ...

  • ACCESSWIRE3 months ago

    Theralase Discovers New Anti-Cancer Vaccine

    TORONTO, ON / ACCESSWIRE / November 20, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • CNW Group3 months ago

    IIROC Trading Resumption - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - Trading resumes in: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Resumption (ET): 13:30  IIROC can make a decision to impose a temporary suspension (halt) ...

  • PR Newswire3 months ago

    IIROC Trading Resumption - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - Trading resumes in: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Resumption (ET): 13:30  IIROC can make a decision to impose a temporary suspension (halt) ...

  • CNW Group3 months ago

    IIROC Trading Halt - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - The following issues have been halted by IIROC: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Reason: Pending Company Contact Halt Time (ET): 11:18 AM IIROC ...

  • PR Newswire3 months ago

    IIROC Trading Halt - TLT

    VANCOUVER , Nov. 13, 2017 /CNW/ - The following issues have been halted by IIROC: Company: THERALASE TECHNOLOGIES INC TSX-Venture Symbol: TLT Reason: Pending Company Contact Halt Time (ET): 11:18 AM IIROC ...

  • Newsfile3 months ago

    IIROC Trade Halt - Theralase Technologies Inc.

    Vancouver, British Columbia--(Newsfile Corp. - November 13, 2017) - The following issues have been halted by IIROC: Company:  Theralase Technologies Inc. TSX-V Symbol: TLT ...

  • ACCESSWIRE3 months ago

    Theralase Researcher Discovers Super Potent Anti-Cancer Drugs

    TORONTO, ON / ACCESSWIRE / November 13, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on ...

  • ACCESSWIRE4 months ago

    Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated

    First Four Patients Treated with Company's Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary and Exploratory Outcome Measures TORONTO, ON / ACCESSWIRE / November 8, 2017 / Theralase Technologies ...

  • ACCESSWIRE4 months ago

    Theralase Anti-Cancer Drugs Independently Reviewed

    TORONTO, ON / ACCESSWIRE / October 31, 2017 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TSX-V: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on the ...

  • ACCESSWIRE4 months ago

    Theralase Research to be Presented at International Conference

    TORONTO, ON / ACCESSWIRE / October 30, 2017 / Theralase Technologies Inc. ( "Theralase®" or the "Company" ) ( TSXV: TLT ) ( OTCQX: TLTFF ), a leading biotech company focused on the ...

  • Baystreet5 months ago

    Stocks in play: Theralase Technologies Inc.

    Has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, ...